Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma

(ECOG-ACRIN Cancer Research Group) The DREAM3R phase 3 clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. DREAM3R aims to enroll 480 patients with non-epithelioid or epithelioid subtype. Patients will be randomized 2:1 to receive durvalumab immunotherapy plus 4-6 cycles of chemotherapy or chemotherapy alone. Patients in the experimental group will continue to receive durvalumab after chemo...